SCHEMBL13638514

SCHEMBL13638514

C=C1CC(Nc2nccc(-c3ccc(-c4ccc(CO)cc4)s3)n2)CC(C)(C)N1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 4/20 0.33
MAPK8 P45983 6/20 0.32
MAPK9 P45984 4/20 0.32
MAPK10 P53779 4/20 0.32
CDK1 P06493 3/20 0.32
CDK4 P11802 3/20 0.32
CCNB1 P14635 3/20 0.32
CCNA2 P20248 3/20 0.32
CCND1 P24385 3/20 0.32
CDK2 P24941 3/20 0.32
CCNA1 P78396 3/20 0.32
MAP3K14 Q99558 4/20 0.32
AKT3 Q9Y243 2/20 0.31
KCNH2 Q12809 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
CCNE1 P24864 1/20 0.31
CCND3 P30281 1/20 0.31
CDK6 Q00534 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638470 0.91 CHEK1 (0.34) IKBKBMAPK8MAPK9MAPK10MAP3K14
SCHEMBL14612849 0.90 IKBKB (0.35) IKBKBMAPK8MAPK9MAPK10CDK1
SCHEMBL13638302 0.88 IKBKB (0.46) IKBKBMAPK8MAPK9MAPK10CDK1
SCHEMBL13638286 0.88 ROCK2 (0.35) IKBKBMAPK8MAPK9MAPK10CDK1
SCHEMBL13638579 0.87 SRC (0.35) IKBKBMAPK8MAPK9MAPK10CDK1
SCHEMBL3477715 0.87 IKBKB (0.36) IKBKBMAPK8MAPK9MAPK10CDK1
SCHEMBL14612804 0.86 MKNK1 (0.39) IKBKBHDAC8
SCHEMBL13638671 0.85 HDAC8 (0.38) HDAC8
SCHEMBL13638501 0.84 HDAC8 (0.41) CDK1CCNB1CCNA2CDK2CCNA1
SCHEMBL14612876 0.84 IKBKB (0.45) IKBKBMAPK8MAPK9MAPK10CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615562-B2 Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents NOVARTIS AG (CH) 2009-11-10 US disclosed
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use NOVARTIS AG (CH) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043048-A1 2-Aminopyrimidine derivatives and their medical use TPMT, IKBKB, CHUK IKBKB 2/4885MAPK8 197/4885MAPK9 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.